Skip to main content

Posts

Showing posts from 2024

ChEMBL & SureChEMBL anniversary symposium

  In 2024 we celebrate the 15th anniversary of the first public release of the ChEMBL database as well as the 10th anniversary of SureChEMBL. To recognise this important landmark we are organising a two-day symposium to celebrate the work achieved by ChEMBL and SureChEMBL, and look forward to its future.   Save the date for the ChEMBL 15 Year Symposium October 1-2, 2024     Day one will consist of four workshops, a basic ChEMBL drug design workshop; an advanced ChEMBL workshop (EUbOPEN community workshop); a ChEMBL data deposition workshop; and a SureChEMBL workshop. Day two will consist of a series of talks from invited speakers, a few poster flash talks, a local nature walk, as well as celebratory cake. During the breaks, the poster session will be a great opportunity to catch up with other users and collaborators of the ChEMBL resources and chat to colleagues, co-workers and others to find out more about how the database is being used. Lunch and refreshments will be pro

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

Updates to the ChEMBL FAQs

If you have a question about the data in ChEMBL you might consider visiting our FAQ page!  We have recently expanded and updated the FAQs; we have included more intuitive categories, mirroring the organisation of our data.  Enquiries are now sorted into general, assay and activity, drug and compound, target, document and data source, interface, download, and schema questions. We have added new answers, including to the questions: How are [protein] isoforms treated by ChEMBL? What are the parameters for the [structure] similarity search? Can you provide more details on ChEMBL releases? Does ChEMBL contain agrochemical data? Our FAQs are searchable, making it easy to navigate to your area of interest.  You can also find help with programmatic access to the database , and a guide to our web interface .   If you want to keep up to date with ChEMBL news and data releases you can subscribe to the Chembl-announce mailing list.   For any questions not answered by our FAQs, please email chemb

SureChEMBL user survey

  (Generated with DALL-E 3 ∙ 11 Janvier 2024 at 11:50 am)   Happy New Year everyone! You already know that we have been working extensively in the last few years to offer a new version of SureChEMBL that can deliver a better user experience. If you did not have the opportunity yet, you can still test the new UI and underlying system . Obviously it is still a beta version but new improvements are deployed weekly and 2024 should be exciting. As said at the announcement, one of the advantages of the new SureChEMBL is that we can finally develop new functionalities! We have a long list in our backlog but not enough time and resources to deliver them all immediately. This is why we would like to offer the SureChEMBL community a say on what we should implemented first. So please have a look at our survey . We gathered ideas that emerged over the last few years and you will be able to vote for what you think we should prioritise. You can also share your own idea if you wish. It should not ta